Chugai Pharmaceutical Co., Ltd. (4519)

Tokyo
Currency in JPY
6,755.0
+130.0(+1.96%)
Closed
4519 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
6,700.06,938.0
52 wk Range
4,572.07,869.0
Key Statistics
Edit
Bid/Ask
6,754.00 / 6,765.00
Prev. Close
6,625
Open
6,724
Day's Range
6,700-6,938
52 wk Range
4,572-7,869
Volume
2.32M
Average Volume (3m)
2.02M
1-Year Change
34.61%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
4519 Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
7,510.0
Upside
+11.18%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 3 consecutive years
Show more

Chugai Pharmaceutical Co., Ltd. Company Profile

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; and research collaboration and option to license agreement with Araris Biotech AG to develop ADCs using Araris AraLinQ technology. The company was founded in 1925 and is headquartered in Chuo-ku, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

Employees
7604
Market
Japan

Compare 4519 to Peers and Sector

Metrics to compare
4519
Peers
Sector
Relationship
P/E Ratio
28.1x19.9x−0.6x
PEG Ratio
1.550.110.00
Price/Book
5.7x1.5x2.6x
Price / LTM Sales
9.3x2.0x3.1x
Upside (Analyst Target)
11.3%24.4%51.7%
Fair Value Upside
Unlock15.6%7.5%Unlock

Analyst Ratings

7 Buy
8 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 7,510.0
(+11.18% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 235.39
Dividend Yield
1.48%
Industry Median 2.28%
Annualized payout
98
Paid unevenly
5-Years Growth
+25.09%
Growth Streak

Earnings

Latest Release
Jan 30, 2025
EPS / Forecast
55.64 / 58.67
Revenue / Forecast
302.07B / 291.01B
EPS Revisions
Last 90 days

People Also Watch

4,070.0
6501
+0.25%
201.2
9434
-0.94%
62,800.0
6861
+0.71%

FAQ

What Is the Chugai Pharmaceutical (4519) Stock Price Today?

The Chugai Pharmaceutical stock price today is 6,755.00

What Stock Exchange Does Chugai Pharmaceutical Trade On?

Chugai Pharmaceutical is listed and trades on the Tokyo stock exchange.

What Is the Stock Symbol for Chugai Pharmaceutical?

The stock symbol for Chugai Pharmaceutical is "4519."

Does Chugai Pharmaceutical Pay Dividends? What’s The Current Dividend Yield?

The Chugai Pharmaceutical dividend yield is 1.45%.

What Is the Chugai Pharmaceutical Market Cap?

As of today, Chugai Pharmaceutical market cap is 11.12T.

What is Chugai Pharmaceutical Earnings Per Share?

The Chugai Pharmaceutical EPS is 235.39.

What Is the Next Chugai Pharmaceutical Earnings Date?

Chugai Pharmaceutical will release its next earnings report on Apr 23, 2025.

From a Technical Analysis Perspective, Is 4519 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.